The Medigene Share
The Medigene share MDG1 (ISIN:DE000A1X3W00 ) is listed at the Frankfurt Stock Exchange since June 2000.
Investors & Media
Welcome to the Investor Relations and Public Relations division of Medigene AG. This is where you will find current information on a variety of subjects, including Medigene AG shares, company news, financial reports and key figures.
Latest News
Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers
Events
12
Nov 2020
Quarterly Announcement Q3 2020
16
Dec 2020
Annual General Meeting 2020 (virtual)
25
Mar 2021
Annual Report 2020
Corporate Governance
Good corporate governance is the basis of our decision-making and monitoring processes. It stands for responsible and value-based leadership and control of the Company for long-term success, goal-oriented and efficient cooperation between the Executive Board and Supervisory Board, respect for the interests of our shareholders and employees, consistently transparent and responsible corporate decisions and an appropriate risk management system.
Contact person
Dr Gary Waanders
Vice President Investor Relations
investor(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20
Dr. Anna Niedl
Director Investor Relations
investor(at)medigene.com
Telefon: +49-89-20 00 33-33 01
Fax: +49-89-20 00 33-29 20